 |
|
|
| |
Real-World Cardiovascular Outcomes of Atazanavir
|
| |
| |
Reported by Jules Levin
17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; October 20-22, 2015; Barcelona, Spain
Lisa Rosenblatt, MD, MPH,1 Amanda M. Farr, MPH,2 Ella Nkhoma, PhD, MPH,3 James K. Nelson, PhD,2
Corey Ritchings, PharmD,1 Stephen Johnston, MA,2
1Bristol-Myers Squibb, Plainsboro, New Jersey, 2Truven Health Analytics, Bethesda, Maryland, 3Bristol-Myers Squibb, Wallingford, Connecticut
from Jules: take note of the percentages for all the comorbidities among those from the Medicaid database, with average ages of 41 ranging up to 52: diabetes 9-10%; hypertension 29-30%; dyslipidemia 10%; renal disease 9.3%, which is double that in the commercial database & many of the percentages are double in Medicaid vs commercial database; anemia 18-19%; HCV 10-11% is triple that in commercial; alcohol abuse is 4.4 to 6% compared to 0.6% in commercial; circulatory diseases [heart disease] 38% vs 22% in commercial.
|
| |
|
|
|
|
|
